Nivolumab continues to show an impressive response that is both prompt and durable in patients with advanced melanoma, according to updated results from a long-term follow-up presented at the 11th International Congress of the Society for Melanoma Research on November 15, 2014.
MRV Research
SMR 2014: Autophagy Regulators: An Emerging Target in Melanoma
During the first plenary session on the second day of the Society for Melanoma Research, 2014 International Congress in Zurich, Switzerland, November 13-16, Targeted Therapies: Genetics and Biology, several researchers presented their thoughts on where they see the future of melanoma research. Various clinical issues faced while treating melanoma patients, including the optimal combination therapies and disease resistance to therapies, were discussed. Scientists also presented data and created a case for novel drug therapies in melanoma
SMR 2014: More Details Presented on Melanoma Diagnostic Test
Much of the news at the Society for Melanoma Research, 2014 International Congress, involves breakthrough therapies for treating metastatic melanoma in its later stages. But the year has brought developments in diagnostics, too. Tools to determine which patients need aggressive treatment and which ones do not are becoming important. As awareness of melanoma grows, more patients arrive at doctors’ offices with suspicious skin marks at earlier stages.
Thin melanomas cause greater number of deaths
More people are dying from melanomas thinner than a dime than from the thicker cancerous skin lesions long thought to be more dangerous, according to a new study from Queensland, Australia.
Thin tumors, which are less often lethal but far more common, accounted for almost one quarter of melanoma deaths in Queensland in the most recent period studied, compared to 14 percent of deaths blamed on thicker tumors.